Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study

Aims: To determine the clinical efficacy, adverse events and side-effect dyspnea of CYP3A4*22 and CYP3A5 expressor status in ticagrelor treated patients. Methods and results: Ticagrelor treated patients from the POPular Genetics randomized controlled trial were genotyped for CYP3A4*22 and CYP3A5*3 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Azzahhafi, Jaouad, Bergmeijer, Thomas O., van den Broek, Wout W. A., Chan Pin Yin, Dean R. P. P., Rayhi, Senna, Peper, Joyce, Bor, Willem L., Claassens, Daniel M. F., van Schaik, Ron H. N., ten Berg, Jurriën M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760790/
https://www.ncbi.nlm.nih.gov/pubmed/36545312
http://dx.doi.org/10.3389/fphar.2022.1032995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760790/
https://www.ncbi.nlm.nih.gov/pubmed/36545312
http://dx.doi.org/10.3389/fphar.2022.1032995

Ejemplares similares